Stock listing
Cboe Canada:RVX Resverlogix Corp. Stock
Canadian listing (Cboe Canada) of Resverlogix Corp. · home listing TSX:RVX
Follow Resverlogix Corp. into a list and get an email when it puts out news.
Home listing price · TSX:RVX
$0.075 CAD 0.000 (0.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TSX:RVX
- Day range
- $0.075 – $0.075 CADNov 20, 2026
- Volume
- 1,000 sharesNov 20, 2026
- Market cap
- $25.82M CADAt the close on Nov 20, 2026 · price × 344.3M shares outstanding
- 52-week range
- $0.070 – $0.150 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2,498 CADMedian day 11,500 shares · 8 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSX:RVX · Home | $0.075 CAD | 0.000 (0.0%) | 1,000 | $0.075 | $0.075 | $0.075 | $0.075 | Close on Nov 20, 2026 |
| OTC:RVXCF | $0.048 USD | -0.002 (-4.4%) | 5,968 | $0.041 | $0.048 | $0.041 | $0.050 | Close on Nov 20, 2026 |
| Frankfurt:RFS | €0.042 EUR | 0.000 (0.0%) | — | €0.042 | €0.042 | €0.042 | €0.042 | Close on Nov 20, 2026 |
| Munich:RFS | €0.042 EUR | -0.006 (-12.6%) | — | €0.048 | €0.048 | €0.042 | €0.048 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSX:RVX · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.075 | 0.000 | 0.0% | $0.075 | $0.075 | $0.075 | 1,000 | |
| $0.075 | -0.005 | -6.3% | $0.075 | $0.075 | $0.075 | 11,000 | |
| $0.080 | +0.005 | +6.7% | $0.080 | $0.080 | $0.080 | 0 | |
| $0.075 | 0.000 | 0.0% | $0.075 | $0.075 | $0.075 | 129,000 | |
| $0.075 | 0.000 | 0.0% | $0.075 | $0.075 | $0.075 | 36,000 | |
| $0.075 | -0.005 | -6.3% | $0.075 | $0.075 | $0.075 | 7,689 | |
| $0.080 | 0.000 | 0.0% | $0.080 | $0.080 | $0.080 | 0 | |
| $0.080 | 0.000 | 0.0% | $0.080 | $0.080 | $0.080 | 5,000 | |
| $0.080 | +0.005 | +6.7% | $0.075 | $0.080 | $0.075 | 70,380 | |
| $0.075 | +0.005 | +7.1% | $0.075 | $0.080 | $0.075 | 46,600 | |
| $0.070 | -0.010 | -12.5% | $0.080 | $0.080 | $0.070 | 216,400 | |
| $0.080 | +0.005 | +6.7% | $0.080 | $0.080 | $0.070 | 64,011 | |
| $0.075 | 0.000 | 0.0% | $0.080 | $0.080 | $0.075 | 2,850 | |
| $0.075 | 0.000 | 0.0% | $0.075 | $0.075 | $0.075 | 4,000 | |
| $0.075 | -0.005 | -6.3% | $0.080 | $0.080 | $0.075 | 42,025 | |
| $0.080 | 0.000 | 0.0% | $0.080 | $0.080 | $0.075 | 20,000 | |
| $0.080 | +0.005 | +6.7% | $0.080 | $0.080 | $0.080 | 0 | |
| $0.075 | -0.005 | -6.3% | $0.075 | $0.075 | $0.075 | 3,000 | |
| $0.080 | -0.010 | -11.1% | $0.080 | $0.080 | $0.080 | 50,178 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 0 | |
| $0.090 | +0.010 | +12.5% | $0.090 | $0.090 | $0.090 | 23,300 | |
| $0.080 | 0.000 | 0.0% | $0.080 | $0.080 | $0.080 | 48,000 | |
| $0.080 | -0.010 | -11.1% | $0.090 | $0.090 | $0.080 | 5,000 | |
| $0.090 | +0.010 | +12.5% | $0.090 | $0.090 | $0.090 | 3,000 | |
| $0.080 | -0.010 | -11.1% | $0.090 | $0.090 | $0.080 | 63,300 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 3,000 | |
| $0.090 | +0.005 | +5.9% | $0.090 | $0.090 | $0.090 | 3,500 | |
| $0.085 | -0.005 | -5.6% | $0.085 | $0.085 | $0.085 | 30,256 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 2,000 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 3,200 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 7,200 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.080 | 91,100 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 5,800 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 90,500 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 56,200 | |
| $0.090 | -0.005 | -5.3% | $0.090 | $0.090 | $0.090 | 33,400 | |
| $0.095 | -0.005 | -5.0% | $0.095 | $0.095 | $0.090 | 61,178 | |
| $0.100 | -0.010 | -9.1% | $0.100 | $0.100 | $0.095 | 8,000 | |
| $0.110 | +0.020 | +22.2% | $0.090 | $0.120 | $0.090 | 113,900 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 0 | |
| $0.090 | 0.000 | 0.0% | $0.100 | $0.100 | $0.090 | 35,700 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 31,600 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 1,100 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 0 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 0 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 80,600 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 2,600 | |
| $0.090 | 0.000 | 0.0% | $0.100 | $0.100 | $0.090 | 16,000 | |
| $0.090 | 0.000 | 0.0% | $0.100 | $0.100 | $0.090 | 75,000 | |
| $0.090 | -0.010 | -10.0% | $0.100 | $0.100 | $0.090 | 42,500 | |
| $0.100 | 0.000 | 0.0% | $0.090 | $0.100 | $0.090 | 4,500 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.090 | 20,100 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 600 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 1,600 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.090 | 64,000 | |
| $0.100 | 0.000 | 0.0% | $0.090 | $0.100 | $0.090 | 12,000 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 31,300 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 500 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 0 | |
| $0.100 | -0.010 | -9.1% | $0.100 | $0.110 | $0.100 | 16,800 | |
| $0.110 | +0.010 | +10.0% | $0.110 | $0.110 | $0.110 | 1,000 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.110 | $0.100 | 20,500 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 33,700 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 4,000 |
- Ticker
- Cboe Canada:RVX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Cboe Canada
- Currency
- CAD
What changed lately
Latest news release · Sep 10, 2026
Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure
Latest deck · Jun 25, 2026
Shareholder Meeting (June 2026)
Shareholder meeting · 14 slides
Latest news
Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure
Sep 10, 2026
Closed $0.09 (-10.0%) on Sep 10, 2026
Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders
Jun 25, 2026
Closed $0.09 (-10.0%) on Jun 26, 2026
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
May 19, 2026
Closed $0.10 (0.0%) on May 20, 2026
Financial Statement Q1 2026
May 15, 2026
Closed $0.10 (0.0%) on May 19, 2026
MD&A Q1 2026
May 15, 2026
Closed $0.10 (0.0%) on May 19, 2026
Resverlogix Announces One-Year Extension of Debenture
May 11, 2026
Closed $0.10 (0.0%) on May 12, 2026
Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
Apr 16, 2026
Closed $0.11 (0.0%) on Apr 16, 2026
Financial Statement Q4 2025
Apr 10, 2026
Closed $0.11 (0.0%) on Apr 13, 2026
Resverlogix Corp. Announces Issuance of MCTO by ASC
Apr 2, 2026
Closed $0.11 (+10.0%) on Apr 2, 2026
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
Mar 31, 2026
Closed $0.10 (-9.1%) on Apr 1, 2026
Resverlogix Corp. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 231 in all · newest Sep 10, 2026 · oldest 2007
- Decks
- 18 decks · latest Jun 25, 2026
Where Resverlogix Corp. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSX:RVX · Home listing | TSX | Canada | CAD |
| LS Exchange:A0DP7L | LS Exchange | Germany | EUR |
| OTC:RVXCF | OTC | United States | USD |
| Lang & Schwarz:A0DP7L | Lang & Schwarz | Germany | EUR |
| Frankfurt:RFS | Frankfurt | Germany | EUR |
| LSE:0VF9 | LSE | United Kingdom | CAD |
| Munich:RFS | Munich | Germany | EUR |
| Cboe Canada:RVX · This page | Cboe Canada | Canada | CAD |
| Stuttgart:RFS | Stuttgart | Germany | EUR |
Valuation
Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $137.0M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P/TSX Composite
- 0.26
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Resverlogix Corp. · TSX:RVX | US$18.01M | US$95.55M | n/a | n/a | n/a | n/a | n/a | n/a | 0.26 |
| IGC Pharma, Inc. · AMEX:IGC | US$19.60M | US$19.19M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.09 |
| Provectus Biopharmaceuticals, Inc. · OTC:PVCT | US$19.12M | US$18.94M | n/a | n/a | n/a | n/a | n/a | n/a | -0.21 |
| LeonaBio, Inc. · NASDAQ:LONA | US$19.03M | −US$12.82M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.04 |
| Cocrystal Pharma, Inc. · NASDAQ:COCP | US$18.30M | US$14.69M | n/a | 33.8× | n/a | 6.8× | n/a | 0.5× | 1.21 |
| Syntara Limited · ASX:SNT | US$18.20M | US$9.23M | n/a | 2.0× | n/a | 1.7× | −129.8% | 0.0× | n/a |
| Marker Therapeutics, Inc. · NASDAQ:MRKR | US$18.17M | US$9.13M | n/a | 4.9× | n/a | 1.7× | −461.1% | 0.0× | 1.49 |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.74M | US$15.65M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Akari Therapeutics PLC · NASDAQ:AKTX | US$16.41M | US$10.66M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.49 |
| Median of the others | US$18.19M | US$13.53M | 10.2× | 2.5× | −178.5% | 0.0× | 1.15 |
Team and board
Officers
| Officer | Role |
|---|---|
| Donald J. McCaffrey | President & Chief Executive Officer |
| Brad Cann | Chief Financial Officer |
| Michael Sweeney | Senior Vice President, Clinical Development |
| Ravi Jahagirdar | Vice President, Pharmacology, Toxicology & Safety |
| Ewelina Kulikowski | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Donald J. McCaffrey | President & Chief Executive Officer |
| Bradley Glass | Director |
| Kenneth J. Zuerblis | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 12, 2026 · After close | 0.0% |
| Q2 2026 | Aug 13, 2026 · After close | 0.0% |
| Q1 2026 | May 14, 2026 · After close | 0.0% |
| Q4 2025 | Mar 31, 2026 · After close | −9.1% |
| Q3 2025 | Nov 12, 2025 · After close | 0.0% |
| Q2 2025 | Aug 14, 2025 · After close | 0.0% |
| Q1 2025 | Jun 4, 2025 · After close | −20.0% |
| Q3 2024 | Nov 7, 2024 · After close | 0.0% |
| Q1 2024 | May 14, 2024 · After close | +8.3% |
| Quarter to Jan 31, 2024 | Mar 31, 2024 | 0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Oct 31, 2023 | Dec 31, 2023 | 0.0% |
| Quarter to Jul 31, 2023 | Sep 30, 2023 | 0.0% |
| Quarter to Apr 30, 2023 | Jun 30, 2023 | 0.0% |
| Quarter to Jan 31, 2023 | Mar 31, 2023 | +6.9% |
| Quarter to Oct 31, 2022 | Dec 31, 2022 | 0.0% |
| Quarter to Jul 31, 2022 | Sep 30, 2022 | 0.0% |
| Quarter to Apr 30, 2022 | Jun 30, 2022 | −7.8% |
| Quarter to Jan 31, 2022 | Mar 31, 2022 | −4.3% |
| Quarter to Oct 31, 2021 | Dec 31, 2021 | −2.0% |
| Quarter to Jul 31, 2021 | Sep 30, 2021 | +2.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (June 2026) | Shareholder meeting | 14 slides | Jun 25, 2026 |
| Shareholder Meeting (June 2023) | Shareholder meeting | 39 slides | Jun 20, 2023 |
| Shareholder Meeting (June 2022) | Shareholder meeting | 18 slides | Jun 20, 2022 |
| Corporate Update (December 2021) | Corporate update | 25 slides | Dec 16, 2021 |
| Shareholder Meeting (June 2021) | Shareholder meeting | 16 slides | Jun 22, 2021 |
| Investor Presentation (February 2021) | Investor deck | 18 slides | Feb 4, 2021 |
| CTAD 2021 | Conference | 12 slides | 2021 |
| Technical Presentation (2021) | Technical | 6 slides | 2021 |
| Technical Presentation (November 2020) | Technical | 17 slides | Nov 16, 2020 |
| Technical Presentation (July 2020) | Technical | 57 slides | Jul 23, 2020 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (June 2020) | Corporate update | 9 slides | Jun 10, 2020 |
| ERA-EDTA 2020 | Conference | 25 slides | Jun 9, 2020 |
| ERA-EDTA 2020 | Conference | 25 slides | Jun 9, 2020 |
| Technical Presentation (November 2019) | Technical | 63 slides | Nov 18, 2019 |
| Investor Presentation (March 2019) | Investor deck | 31 slides | March 2019 |
| Investor Presentation (January 2019) | Investor deck | 31 slides | Jan 7, 2019 |
| Investor Presentation (December 2018) | Investor deck | 31 slides | December 2018 |
| Investor Presentation (November 2018) | Investor deck | 30 slides | November 2018 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 437.5K | 476.7K | 729.5K | 0 | 0 | |||||
| Gross profit | -437.5K | -476.7K | -729.5K | 0 | 0 | |||||
| Research and development | 2.77M | 2.85M | 3.25M | 5.51M | 4.51M | 6.40K | 15.8M | 32.3K | 37.8M | 29.9M |
| Selling, general and administrative | 1.96M | 1.79M | 3.02M | 6.94M | 11.1M | 5.33M | 6.78M | 6.51K | 4.07M | 4.27M |
| Operating income | -5.20M | -6.37M | -6.26M | -12.7M | -16.0M | -14.6K | -22.6M | -38.7K | -30.9M | -34.1M |
| Depreciation and amortization | 437.5K | 348.0K | 716.0K | 1.01M | 1.11M | 1.03M | 1.03M | 356.0K | 358.0K | 377.0K |
| EBITDA | -4.77M | -6.02M | -5.55M | -11.7M | -14.9M | 1.01M | -21.6M | 317.3K | -30.5M | -33.8M |
| Interest expense | 4.33M | 4.20M | 1.87M | 1.63M | 727.0K | 2.98M | 3.57M | 5.63M | 5.45M | 7.03M |
| Income before tax | -7.94M | -7.62M | -16.7M | -3.59M | -24.8M | 2.50K | 118.1M | -162.8K | -58.3M | -46.1M |
| Income tax | -39.7K | 14.0K | 15.0K | 18.0K | 12.0K | 32 | 27.0K | 29 | 47.0K | 83.0K |
| Net income | -7.90M | -7.63M | -16.7M | -3.61M | -24.8M | 2.46K | 118.0M | -162.8K | -58.3M | -46.2M |
| Earnings per share, basic | -0.03 | -0.03 | -0.06 | -0.01 | -0.10 | 0.00 | 0.53 | -0.00 | -0.42 | -0.44 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 107.8K | 99.0K | 5.00K | 40.0K | 6.00K | 87.0K | 4.00K | 7.69M | 121.0K | 1.35M |
| Receivables | 910.3K | 346.6K | 104.0K | 323.0K | 310.0K | 848.0K | 920.0K | 978.0K | 216.0K | 245.0K |
| Inventory | 434.2K | 996.0K | 300.0K | 2.37M | 2.45M | 584.0K | 1.55M | 1.16M | 3.06M | 3.34M |
| Current assets | 1.60M | 1.54M | 564.0K | 2.89M | 2.95M | 1.94M | 3.18M | 10.6M | 4.04M | 5.65M |
| Property, plant and equipment | 0 | 426.0K | 1.04M | 1.46M | 1.96M | 350.0K | 468.0K | 628.0K | ||
| Total assets | 7.93M | 7.34M | 6.57M | 8.12M | 9.98M | 10.7M | 11.4M | 16.3M | 8.28M | 10.9M |
| Accounts payable | 18.2M | 4.30M | 14.5M | 14.1M | 8.70M | 6.94M | 7.88M | 8.19M | 22.2M | 12.2M |
| Current liabilities | 44.0M | 26.3M | 26.9M | 22.7M | 17.4M | 11.8M | 28.7M | 86.6M | 38.0M | 69.7M |
| Long-term debt | 61.9M | 53.3M | 43.7M | 137.4M | 54.0M | 42.7M | ||||
| Total debt | 72.8M | 82.0M | 9.91M | 6.49M | 7.04M | 996.0K | 13.2M | 14.8M | 708.0K | 48.6M |
| Total liabilities | 96.7M | 89.1M | 81.0M | 67.4M | 69.9M | 50.6M | 75.5M | 224.0M | 92.0M | 112.4M |
| Shareholders' equity | -88.8M | -81.7M | -74.5M | -59.3M | -59.9M | -39.9M | -64.1M | -207.7M | -83.7M | -101.6M |
| Shares outstanding | 285.1M | 276.6M | 270.0M | 254.4M | 239.9M | 235.0M | 221.4M | 202.7M | 137.7M | 105.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3.73M | -3.89M | -2.51M | -3.54M | -8.02M | -4.40K | -17.3M | -48.8M | -25.1M | -22.7M |
| Capital spending | -9.16K | -472.0K | -448.0K | -450.0K | -877.0K | -13 | -500.0K | -622.0K | -537.0K | -559.0K |
| Free cash flow | -3.73M | -4.36M | -2.96M | -3.99M | -8.90M | -4.41K | -17.8M | -49.5M | -25.7M | -23.2M |
| Cash from investing | -660.4K | -377.0K | -516.0K | -473.0K | -833.0K | -426 | -576.0K | -731.0K | -360.0K | -652.0K |
| Cash from financing | 4.39M | 4.36M | 2.99M | 4.06M | 8.81M | 4.95K | 10.2M | 57.1M | 23.3M | -2.38M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Share buybacks | 278.0K | 4.70M | 4.02M | 4.04M | 16.4M | 47.6M | 83.2M | 250.0K | ||
| Change in cash | 4.12K | 94.0K | -35.0K | 34.0K | -81.0K | -7.68K | -7.68M | 7.57M | -1.23M | -26.8M |
Cap table
Built by 6ix from Resverlogix Corp.’s releases
- Common shares
- 344,286,709
- Fully diluted
- 347,186,709
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 344,286,709 |
| Options and RSUs | 2,900,000 |
Warrants and options
| Lot |
|---|
| Stock options · C$0.09 · expiry not stated |
| RSUs · expiry not stated |
| Stock options · C$0.09 · expiry not stated |
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 344,286,709 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| A. Brad Cann | Chief Financial Officer · Since at least Apr 11, 2026 |
| Bradley Glass | Director · Since at least Nov 18, 2025 |
| Donald J. McCaffrey | President & Chief Executive Officer · Since at least Apr 11, 2026 |
| Ewelina Kulikowski | Chief Scientific Officer · Since at least Sep 10, 2026 |
| Kenneth J. Zuerblis | Board Member · Since at least Jun 26, 2026 |
| Michael Sweeney | Senior Vice President, Clinical Development · Since at least Nov 5, 2026 |
| Ravi Jahagirdar | Vice President, Pharmacology, Toxicology & Safety · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Resverlogix Corp.